Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.43 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258221 | 0.90 | LYPLA1 (0.42) | TSHRGBA1ALDH1A1LMNAHTT | |
| SCHEMBL11676157 | 0.89 | LYPLA1 (0.41) | TSHRGBA1LMNAHTTLYPLA1 | |
| SCHEMBL11677202 | 0.85 | HTR7 (0.46) | TSHRGBA1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL12258219 | 0.85 | PPARG (0.40) | TSHRGBA1ALDH1A1LMNAHTT | |
| SCHEMBL11679757 | 0.84 | TAAR1 (0.47) | TAAR1 | |
| SCHEMBL8352890 | 0.82 | LYPLA1 (0.58) | TSHRALDH1A1LMNAHTTLYPLA1 | |
| SCHEMBL25359144 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL30678583 | 0.81 | LYPLA1 (0.57) | TSHRALDH1A1LMNAHTTLYPLA1 | |
| SCHEMBL9768334 | 0.81 | PPARG (0.56) | TSHRALDH1A1LMNAHTTLYPLA1 | |
| SCHEMBL1637985 | 0.81 | ALOX15 (0.43) | TSHRALDH1A1HTTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394233-B2 | ROS-activated compounds as selective anti-cancer therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394233-B2 | ROS-activated compounds as selective anti-cancer therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-09-05 | — | — | US | disclosed |
| US-4051117-A | Triazole-azo-phenyl cationic dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4051084-A | BENZOTHIAZOLE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | ROS1, NOX4, NOX1 | TSHR 4113/4885GBA1 1627/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.